Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (10)

2022

  1. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441

    European Urology

2021

  1. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

2019

  1. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology

    Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 420-432

  2. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy

    Radiotherapy and Oncology, Vol. 141, pp. 156-163

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

    Clinical and Translational Oncology, Vol. 17, Núm. 3, pp. 223-229

  2. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

  3. Nomogramme für die Prognose eines biochemischen Rezidivs beim Prostatakarzinom nach Strahlentherapie und Androgendeprivationstherapie

    Strahlentherapie und Onkologie, Vol. 191, Núm. 10, pp. 792-800

  4. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272